Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

Authors :: Kathleen B. Schwarz
Bandita Parhy
William F. Balistreri
Benedetta Massetto
Suzanne Whitworth
Karen F. Murray
Chia Hsiang Hsueh
Philip J. Rosenthal
Jiang Shao
Diana M. Brainard
Rosie Hague
Girish S. Rao
Naveen Mittal
Michael R. Narkewicz
Winita Hardikar
Jonathan Honegger
Sanjay Bansal
Source :: Hepatology (Baltimore, Md.)
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.
Abstract: For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct‐acting antiviral agents. We therefore evaluated the safety and efficacy of ledipasvir‐sofosbuvir in HCV‐infected children aged 3 to

Tools